ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 0542 • ACR Convergence 2020

    Examining the Long-Term and Short-Term Day-To-Day Pain Variability in Inflammatory and Non-Inflammatory Rheumatic and Musculoskeletal Diseases Using Multilevel and Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study

    Huai Leng Pisaniello1, Mark Lunt2, John McBeth3 and William Dixon2, 1University of Adelaide, Kidman Park, South Australia, Australia, 2Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, 3University of Manchester, Manchester, United Kingdom

    Background/Purpose: Chronic pain is common in rheumatic and musculoskeletal diseases (RMDs), yet the patterns and the extent of variability over time are poorly understood. Real-time…
  • Abstract Number: 1493 • ACR Convergence 2020

    Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis

    Stephanie Shoop-Worrall1, Kimme Hyrich2, Lucy Wedderburn3, Wendy Thomson4 and Nophar Geifman5, 1Centre for Health Informatics, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, 2Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 3UCL, UCLH, GOS Institute of Child Health, London, United Kingdom, 4Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 5Centre for Health Informatics, The University of Manchester, Manchester

    Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…
  • Abstract Number: 0672 • ACR Convergence 2020

    Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares

    Natalie McCormick1, Chio Yokose1, Clara Chen2, Tuhina Neogi3, David Hunter4, Hyon Choi5 and Yuqing Zhang6, 1Massachusetts General Hospital, Boston, MA, 2Boston University School of Public Health, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 6Massachusetts General Hospital, Harvard Medical School, Boston

    Background/Purpose: Cross-sectional radiologic evidence suggests monosodium urate crystal deposition among gout patients is a symmetrical phenomenon,1 but no study has examined the longitudinal patterns in…
  • Abstract Number: 1512 • ACR Convergence 2020

    Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis

    Andrea Fava1, Avi Rosenberg2, Serena Bagnasco2, Paride Fenaroli2, Jessica Li1, Jose Monroy-Trujillo2, Derek Fine2 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, 3Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
  • Abstract Number: 0713 • ACR Convergence 2020

    Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry

    Daniel J Lovell1, Hermine Brunner2, Nikolay Tzaribachev3, Esi Morgan2, Gabriele Simonini4, Thomas Griffin5, Ekaterina Alexeeva6, John Bohnsack7, Andrew Zeft8, Gerd Horneff9, Richard Vehe10, Valda Stanevicha11, Stacey Tarvin12, Maria Trachana13, Adam Huber14, Ilonka Orban15, Jason Dare16, Ivan Foeldvari17, Pierre Quartier18, Alyssa Dominique19, Tzuyung Douglas Kou19, Robert Wong19, Alberto Martini20 and Nicolino Ruperto20, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 4Anna Meyer Children's Hospital, Firenze, Italy, 5Levine Children's Hospital, Charlotte, NC, 6Scientific Center of Children’s Health of RAMS, Moscow, Russia, 7University of Utah and Primary Children's Hospital, Cincinnati, OH, 8Cleveland Clinic, Cleveland, OH, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10University of Minnesota, Minneapolis, MN, 11Riga Stradins University, Riga, Latvia, 12Riley Children’s Health, Indianapolis, IN, 13Aristotle University of Thessaloniki, Thessaloníki, Greece, 14Dalhousie University, Halifax, NS, Canada, 15National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 16University of Arkansas for Medical Sciences, Little Rock, AR, 17Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 18Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 19Bristol-Myers Squibb Company, Princeton, NJ, 20PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
  • Abstract Number: 1635 • ACR Convergence 2020

    Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database

    Amy Kenneally1, Frédérique Bariguian2, Richard Petruschke1, Arlene Tave3, Jess Edison4, Nicholas M. Sicignano5 and Francis Barbone1, 1GSK Consumer Healthcare, Warren, NJ, 2GSK Consumer Healthcare S.A., Nyon, Switzerland, 3PharmaLex US Corporation, Fairfax, VA, 4Walter Reed National Military Medical Center, Bethesda, 5Health ResearchTx LLC., Prevose, PA

    Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
  • Abstract Number: 0748 • ACR Convergence 2020

    Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis

    Andreas Kerschbaumer1, Gabriela Supp2, Farideh Alasti1, Josef Smolen2 and Daniel Aletaha1, 1Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 2Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
  • Abstract Number: 1751 • ACR Convergence 2020

    Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center

    Elston He1, Eli Cornblath2, Pratyusha Yalamanchi3, Alexis Ogdie2, Joshua Baker2 and Michael George2, 1Synovium, Inc., Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
  • Abstract Number: 0769 • ACR Convergence 2020

    Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study

    Fenne Wouters1, Ellis Niemantsverdriet1, Nazike Salioska1, Annemarie Dorjée1, René Toes1 and Annette van der Helm - van Mil2, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Auto-antibodies in rheumatoid arthritis (RA) are often present years before disease onset but their mere presence does not seem enough to induce RA. Several…
  • Abstract Number: 1812 • ACR Convergence 2020

    Longitudinal Blood DNA Methylation in a Multi-ethnic Cohort of SLE Patients

    Cristina Lanata1, Joanne Nititham2, Kim Taylor2, Sharon Chung2, Laura Trupin1, Patricia Katz3, Maria Dall'Era4, Jinoos Yazdany1, Marina Sirota1, Lisa Barcellos5 and Lindsey Criswell6, 1UCSF, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3University of California, San Francisco, Novato, CA, 4Division of Rheumatology, University of California, San Francisco, CA, 5UC Berkeley, Berkeley, CA, 6Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA

    Background/Purpose: Cross-sectional studies have shown associations between DNA methylation differences in whole blood with Systemic Lupus Erythematosus (SLE) status and outcomes such as lupus nephritis.…
  • Abstract Number: 0779 • ACR Convergence 2020

    Antibody Responses to Epstein-Barr Virus Are Altered in the Pre-Clinical Period of Rheumatoid Arthritis

    Sabrina Fechtner1, Heather Berens2, Elizabeth Bemis3, M Kristen Demoruelle2, Carla J. Guthridge4, John Harley5, Judith James6, Jess Edison7, Kevin D. Deane8, Jill Norris9 and V. Michael Holers2, 1University of Colorado, Aurora, CO, 2University of Colorado, Denver, CO, 3Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, 7Walter Reed National Military Medical Center, Bethesda, 82 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 9Colorado School of Public Health, Aurora, CO

    Background/Purpose: Viral infections, including infection with Epstein-Barr virus (EBV), have been suggested as environmental risk factors for rheumatoid arthritis (RA). EBV infections are known to…
  • Abstract Number: 1815 • ACR Convergence 2020

    Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis

    Doua Azzouz1, Ze Chen2, Zhi Li3, Peter Izmirly4, Jing Deng1, David Fenyo3, Jill Buyon1, Alexander Alekseyenko5 and Gregg Silverman6, 1Department of Medicine, NYU School of Medicine, New York, NY, 2Department of Microbiology, NYU School of Medicine, New York, NY, 3Institute for Systems Genetics, NYU School of Medicine, New York, NY, 4Department of Medicine, New York University School of Medicine, New York, NY, 5Medical University of South Carolina, Charleston, SC, 6Laboratory of B cell immunobiology, Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: From a cross-sectional cohort, we have recently identified a candidate human gut pathobiont, Ruminococcus gnavus (RG) of the Lachnospiraceae family and Blautia genus that…
  • Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium

    Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years

    Jessica Neely1, Adam Huber 2 and Susan Kim 3 for the CARRA investigators, 1University of California, San Francisco, San Francisco, California, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3University of California, San Francisco, San Francisco

    Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
  • Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium

    Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

    Mia Glerup1, Ellen D Arnstad 2, Veronika Rypdal 3, Suvi Peltoniemi 4, Kristiina Aalto 5, Marite Rygg 6, Susan Nielsen 7, Anders Fasth 8, Lillemor Berntson 9, Ellen Nordal 3 and Troels Herlin 10, 1Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, 3Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 4Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, 5Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 6Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, 7Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, 8Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 9Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark

    Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
  • Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting

    Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome

    Eun Hye Park1, You-Jung Ha 1, Eun Ha Kang 1, Yeong-Wook Song 2 and Yun Jong Lee 3, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 2Seoul National University Hospital, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea

    Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology